Today

Agents

Chat

Arena

Discover

More

App

ANI Pharmaceuticals Q2 Adjusted EPS USD 2.21 Vs. IBES Estimate USD 2.05 - ANIP News | Rallies

ANI Pharmaceuticals Q2 Adjusted EPS USD 2.21 Vs. IBES Estimate USD 2.05

ANIP•2026-08-07

Quarterly results and outlook

Aug. 7 (Reuters) - ANI Pharmaceuticals Q2 adjusted EBITDA was USD 71.6 million.

Q2 EPS was USD 1.05
Q2 net income was USD 24.7 million
FY adjusted EBITDA outlook is USD 285-300 million
FY revenue outlook is USD 1,080-1,140 million, versus the IBES estimate of USD 1,119 million
FY adjusted EPS outlook is USD 9.19-9.69, versus the IBES estimate of USD 9.45

Related News

Encompass Health Corp <EHC.N>: Truist Securities Raises Target Price to $150 from $140

EHC•2026-08-07

Take-Two sticks to annual bookings outlook, says on track for 'GTA VI' November launch

TTWO•2026-08-07

Honeywell Aerospace Inc <HONA.O>: Morgan Stanley cuts target price to $205.00 from $235.00

HON

•

2026-08-07

Six Flags Entertainment <FUN.N>: Deutsche Bank cuts target price to $20 from $29

FUN•2026-08-07

Take-Two FY27 Q1 net loss widens to $34.1 million; revenue rises 2% to $1.53 billion

TTWO•2026-08-07